Aptevo Therapeutics (APVO) Depreciation & Amortization (CF) (2015 - 2026)

Aptevo Therapeutics has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $35000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 42.62% year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $214000.0 (down 30.29% YoY) and the FY2025 annual result came in at $240000.0, down 31.82% from the prior year.
• Depreciation & Amortization (CF) fell to $35000.0 in Q1 2026 per APVO's latest filing, from $81000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $276000.0 in Q2 2022 and troughed at $35000.0 in Q1 2026.
• A 5-year average of $123235.3 and a median of $106000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 14.08% in 2025, down 46.15% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $161000.0 in 2022, then retreated by 27.95% to $116000.0 in 2023, then plunged by 38.79% to $71000.0 in 2024, then increased by 14.08% to $81000.0 in 2025, then slumped by 56.79% to $35000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $35000.0, $81000.0, and $49000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.